Simulations Plus, Inc. (NASDAQ:SLP) is a company that develops cutting-edge software for the pharmaceutical industry. It leverages artificial intelligence and modeling to help create and test new drugs. Simulations Plus's main products, like GastroPlus and DDDPlus, are widely used by drug companies, biotech firms, and regulatory agencies for critical research and development.
Analysts have shown a consistent view of Simulations Plus's stock over the past year. The consensus price target, which is the average target price predicted by analysts, has remained stable at $18.50. This stability suggests that, until recently, experts did not expect major changes in the company's financial performance or market standing.
However, recent events introduce new concerns for investors. The law firm Johnson Fistel, PLLP has launched an investigation into Simulations Plus on behalf of investors who have suffered losses. This action follows a cut in the company's revenue guidance and new accounting disclosures that have drawn scrutiny.
The investigation comes after Simulations Plus reported its second-quarter results on April 3, 2024. At that time, the company had maintained its full-year revenue guidance between $90 million and $93 million. The subsequent guidance cut is a key factor behind the current legal examination of the company's statements.
As highlighted by PR Newswire, the investigation is examining whether investor losses may be recoverable under federal securities laws. These laws are designed to protect investors from being misled by a company's public statements. The firm is looking into the disclosures made by Simulations Plus leading up to the guidance change.
